Ordastobart
Monoclonal antibody
Also known as INBRX-106, ES102
Evidence outlook
Mid-stage readout reported
A Phase 2/3 readout has been reported. The trial rows below carry the recorded result.
Latest reported trial: HexAgon-HN (NCT06295731) · Phase 2/3 · met primary endpoint · grade pending
Also in development:Non-Small Cell Lung Cancer · Phase 2
Company guidance: data expected mid-2027 (Inhibrx Biosciences, Inc, 13 Nov 2026). “The Company expects initial results from its Phase 1/2 study of ordastobart (INBRX-106) in the perioperative setting of non-small cell lung cancer (NSCLC) in mid-2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
HexAgon-HN NCT06295731 · Head and Neck Squamous Cell Carcinoma Registry: NCT06295731 | 2/3 | Phase 2: Objective Response Rate by investigator (ORRinv) (From randomization to progressive disease (PD) or death (up to 1 year)); Phase 3: Progression-Free Survival by Investigator (PFSinv) (From randomization to PD or death (up to 4 years)); Phase 3: Overall Survival (OS) (From randomization until death from any cause (up to 4 years)) 2029-12 | Phase 2 portion (randomized, primary endpoint ORR): confirmed ORR 48.3% with INBRX-106 + pembrolizumab vs 26.5% with pembrolizumab alone; interim median PFS 9.6 months (Inhibrx, 2026-09-08). The Phase 3 portion has not read out. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other OX40 (agonist) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Head and Neck Squamous Cell Carcinoma: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ordastobart: this drug | Phase 2/3 | Monoclonal antibody | OX40 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cetuximab | Approved | Monoclonal antibody | EGFR | Partial signal | NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). | |
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj) | Approved | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| NBTXR3 | Phase 3 | Nanoparticle | Hafnium-oxide nanoparticle radioenhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ozuriftamab Vedotin | Phase 2 | Antibody–drug conjugate | ROR2 | Partial signal | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| Pepinemab | Phase 1/2 | Monoclonal antibody | SEMA4D | not yet graded | No reviewed efficacy summary in this indication | |
| Buparlisib | Discontinued | Small molecule | PI3K inhibitor (pan-class I) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ordastobart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent